Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens

Molecular Therapy Methods and Clinical Development

Volumn 3, Issue , 2016, Pages 16030-

  Afkhami, Sam ^a   Yao, Yushi ^a   Xing, Zhou ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BCG VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE;

ADENOVIRIDAE; CHIMPANZEE; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; MOLECULAR BIOLOGY; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROTYPE; TUBERCULOSIS; VACCINATION;

EID: 85015198502     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2016.30     Document Type: Review

References (90)

1. 1 Volpers, C, Kochanek, S, Adenoviral vectors for gene transfer and therapy. J Gene Med 6:suppl. 1 (2004), S164–S171.
2. 2 Tatsis, N, Ertl, HC, Adenoviruses as vaccine vectors. Mol Ther 10 (2004), 616–629.
3. 3 Lasaro, MO, Ertl, HC, New insights on adenovirus as vaccine vectors. Mol Ther 17 (2009), 1333–1339.
4. 4 Majhen, D, Calderon, H, Chandra, N, Fajardo, CA, Rajan, A, Alemany, R, et al. Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field. Hum Gene Ther 25 (2014), 301–317.
5. 5 Sheridan, C, Gene therapy finds its niche. Nat Biotechnol 29 (2011), 121–128.
6. 6 Lycke, N, Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 12 (2012), 592–605.
7. 7 Lai, R, Afkhami, S, Haddadi, S, Jeyanathan, M, Xing, Z, Mucosal immunity and novel tuberculosis vaccine strategies: route of immunisation-determined T-cell homing to restricted lung mucosal compartments. Eur Respir Rev 24 (2015), 356–360.
8. 8 Suleman, M, Galea, S, Gavard, F, Merillon, N, Klonjkowski, B, Tartour, E, et al. Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset. Vaccine 29 (2011), 5892–5903.
9. 9 Robinson, CM, Singh, G, Henquell, C, Walsh, MP, Peigue-Lafeuille, H, Seto, D, et al. Computational analysis and identification of an emergent human adenovirus pathogen implicated in a respiratory fatality. Virology 409 (2011), 141–147.
10. 10 McConnell, MJ, Imperiale, MJ, Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 15 (2004), 1022–1033.
11. 11 Colloca, S, Barnes, E, Folgori, A, Ammendola, V, Capone, S, Cirillo, A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med, 4, 2012, 115ra2.
12. 12 Tatsis, N, Tesema, L, Robinson, ER, Giles-Davis, W, McCoy, K, Gao, GP, et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther 13 (2006), 421–429.
13. 13 Zaiss, AK, Machado, HB, Herschman, HR, The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem 108 (2009), 778–790.
14. + T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci USA 109 (2012), E3503–E3512.
15. 15 Bouard, D, Alazard-Dany, D, Cosset, FL, Viral vectors: from virology to transgene expression. Br J Pharmacol 157 (2009), 153–165.
16. 16 Stanton, RJ, McSharry, BP, Armstrong, M, Tomasec, P, Wilkinson, GW, Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function. Biotechniques 45 (2008), 659–662, 664.
17. 17 Sakhuja, K, Reddy, PS, Ganesh, S, Cantaniag, F, Pattison, S, Limbach, P, et al. Optimization of the generation and propagation of gutless adenoviral vectors. Hum Gene Ther 14 (2003), 243–254.
18. 18 Graham, FL, Prevec, L, Methods for construction of adenovirus vectors. Mol Biotechnol 3 (1995), 207–220.
19. 19 Davis, AR, Wivel, NA, Palladino, JL, Tao, L, Wilson, JM, Construction of adenoviral vectors. Mol Biotechnol 18 (2001), 63–70.
20. 20 Weaver, EA, Nehete, PN, Buchl, SS, Senac, JS, Palmer, D, Ng, P, et al. Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS One, 4, 2009, e5059.
21. 21 Cao, H, Machuca, TN, Yeung, JC, Wu, J, Du, K, Duan, C, et al. Efficient gene delivery to pig airway epithelia and submucosal glands using helper-dependent adenoviral vectors. Mol Ther Nucleic Acids, 2, 2013, e127.
22. 22 Muruve, DA, Cotter, MJ, Zaiss, AK, White, LR, Liu, Q, Chan, T, et al. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol 78 (2004), 5966–5972.
23. 23 Danthinne, X, Imperiale, MJ, Production of first generation adenovirus vectors: a review. Gene Ther 7 (2000), 1707–1714.
24. 24 Kovesdi, I, Hedley, SJ, Adenoviral producer cells. Viruses 2 (2010), 1681–1703.
25. 25 Havenga, M, Vogels, R, Zuijdgeest, D, Radosevic, K, Mueller, S, Sieuwerts, M, et al. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. J Gen Virol 87 (2006), 2135–2143.
26. 26 Murakami, P, Pungor, E, Files, J, Do, L, van Rijnsoever, R, Vogels, R, et al. A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles. Hum Gene Ther 13 (2002), 909–920.
27. 27 Gao, G, Zhou, X, Alvira, MR, Tran, P, Marsh, J, Lynd, K, et al. High throughput creation of recombinant adenovirus vectors by direct cloning, green-white selection and I-Sce I-mediated rescue of circular adenovirus plasmids in 293 cells. Gene Ther 10 (2003), 1926–1930.
28. 28 Schaack, J, Langer, S, Guo, X, Efficient selection of recombinant adenoviruses by vectors that express beta-galactosidase. J Virol 69 (1995), 3920–3923.
29. 29 Chartier, C, Degryse, E, Gantzer, M, Dieterle, A, Pavirani, A, Mehtali, M, Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 70 (1996), 4805–4810.
30. 30 Ng, P, Graham, FL, Construction of first-generation adenoviral vectors. Methods Mol Med 69 (2002), 389–414.
31. 31 Luo, J, Deng, ZL, Luo, X, Tang, N, Song, WX, Chen, J, et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2 (2007), 1236–1247.
32. 32 Mizuguchi, H, Kay, MA, Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 9 (1998), 2577–2583.
33. 33 Zhou, D, Zhou, X, Bian, A, Li, H, Chen, H, Small, JC, et al. An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat Protoc 5 (2010), 1775–1785.
34. 34 Kallel, H, Kamen, AA, Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials. Biotechnol J 10 (2015), 741–747.
35. 35 Kamen, A, Henry, O, Development and optimization of an adenovirus production process. J Gene Med 6:suppl. 1 (2004), S184–S192.
36. 36 Lusky, M, Good manufacturing practice production of adenoviral vectors for clinical trials. Hum Gene Ther 16 (2005), 281–291.
37. 37 WHO, WHO Global Tuberculosis Report 2015, 2015, World Health Organization, Geneva.
38. 38 Cooper, AM, Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27 (2009), 393–422.
39. 39 Nunes-Alves, C, Booty, MG, Carpenter, SM, Jayaraman, P, Rothchild, AC, Behar, SM, In search of a new paradigm for protective immunity to TB. Nat Rev Microbiol 12 (2014), 289–299.
40. 40 Forbes, EK, Sander, C, Ronan, EO, McShane, H, Hill, AV, Beverley, PC, et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 181 (2008), 4955–4964.
41. 41 Wang, J, Thorson, L, Stokes, RW, Santosuosso, M, Huygen, K, Zganiacz, A, et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 173 (2004), 6357–6365.
42. 42 Horvath, CN, Shaler, CR, Jeyanathan, M, Zganiacz, A, Xing, Z, Mechanisms of delayed anti-tuberculosis protection in the lung of parenteral BCG-vaccinated hosts: a critical role of airway luminal T cells. Mucosal Immunol 5 (2012), 420–431.
43. 43 Santosuosso, M, McCormick, S, Zhang, X, Zganiacz, A, Xing, Z, Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 74 (2006), 4634–4643.
44. 44 Santosuosso, M, McCormick, S, Roediger, E, Zhang, X, Zganiacz, A, Lichty, BD, et al. Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization. J Immunol 178 (2007), 2387–2395.
45. 45 Huygen, K, The immunodominant T-cell epitopes of the mycolyl-transferases of the antigen 85 complex of M. tuberculosis. Front Immunol, 5, 2014, 321.
46. 46 Jeyanathan, M, Shao, Z, Yu, X, Harkness, R, Jiang, R, Li, J, et al. AdHu5Ag85A respiratory mucosal boost immunization enhances protection against pulmonary tuberculosis in BCG-primed non-human primates. PLoS One, 10, 2015, e0135009.
47. 47 Xing, Z, McFarland, CT, Sallenave, JM, Izzo, A, Wang, J, McMurray, DN, Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS One, 4, 2009, e5856.
48. 48 Mu, J, Jeyanathan, M, Shaler, CR, Horvath, C, Damjanovic, D, Zganiacz, A, et al. Respiratory mucosal immunization with adenovirus gene transfer vector induces helper CD4 T cell-independent protective immunity. J Gene Med 12 (2010), 693–704.
49. 49 Dean, GS, Clifford, D, Whelan, AO, Tchilian, EZ, Beverley, PC, Salguero, FJ, et al. Protection induced by simultaneous subcutaneous and endobronchial vaccination with BCG/BCG and BCG/adenovirus expressing antigen 85A against Mycobacterium bovis in cattle. PLoS One, 10, 2015, e0142270.
50. 50 Smaill, F, Jeyanathan, M, Smieja, M, Medina, MF, Thanthrige-Don, N, Zganiacz, A, et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med, 5, 2013, 205ra134.
51. 51 Dudareva, M, Andrews, L, Gilbert, SC, Bejon, P, Marsh, K, Mwacharo, J, et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 27 (2009), 3501–3504.
52. 52 Sumida, SM, Truitt, DM, Lemckert, AA, Vogels, R, Custers, JH, Addo, MM, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174 (2005), 7179–7185.
53. 53 Thorner, AR, Vogels, R, Kaspers, J, Weverling, GJ, Holterman, L, Lemckert, AA, et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol 44 (2006), 3781–3783.
54. 54 Radosevic, K, Wieland, CW, Rodriguez, A, Weverling, GJ, Mintardjo, R, Gillissen, G, et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun 75 (2007), 4105–4115.
55. 55 Darrah, PA, Bolton, DL, Lackner, AA, Kaushal, D, Aye, PP, Mehra, S, et al. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge. J Immunol 193 (2014), 1799–1811.
56. 56 Hokey, DA, Wachholder, R, Darrah, PA, Bolton, DL, Barouch, DH, Hill, K, et al. A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine: evidence for transient t cell responses in peripheral blood and robust sustained responses in the lungs. Hum Vaccin Immunother 10 (2014), 2199–2210.
57. 57 Churchyard, GJ, Snowden, MA, Hokey, D, Dheenadhayalan, V, McClain, JB, Douoguih, M, et al. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3). Vaccine 33 (2015), 1890–1896.
58. 58 Kagina, BM, Tameris, MD, Geldenhuys, H, Hatherill, M, Abel, B, Hussey, GD, et al., 018-402 Clinical Lab study team, The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses. Vaccine 32 (2014), 5908–5917.
59. 59 Abel, B, Tameris, M, Mansoor, N, Gelderbloem, S, Hughes, J, Abrahams, D, et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med 181 (2010), 1407–1417.
60. 60 Sheehan, S, Harris, SA, Satti, I, Hokey, DA, Dheenadhayalan, V, Stockdale, L, et al. A phase I, open-label trial, evaluating the safety and immunogenicity of candidate tuberculosis vaccines AERAS-402 and MVA85A, administered by prime-boost regime in BCG-vaccinated healthy adults. PLoS One, 10, 2015, e0141687.
61. 61 Tameris, M, Hokey, DA, Nduba, V, Sacarlal, J, Laher, F, Kiringa, G, et al. A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants. Vaccine 33 (2015), 2944–2954.
62. 62 Johnson, MJ, Björkström, NK, Petrovas, C, Liang, F, Gall, JG, Loré, K, et al. Type I interferon-dependent activation of NK cells by rAd28 or rAd35, but not rAd5, leads to loss of vector-insert expression. Vaccine 32 (2014), 717–724.
63. 63 Johnson, MJ, Petrovas, C, Yamamoto, T, Lindsay, RW, Loré, K, Gall, JG, et al. Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity. J Immunol 188 (2012), 6109–6118.
64. 64 Jeyanathan, M, Damjanovic, D, Shaler, CR, Lai, R, Wortzman, M, Yin, C, et al. Differentially imprinted innate immunity by mucosal boost vaccination determines antituberculosis immune protective outcomes, independent of T-cell immunity. Mucosal Immunol 6 (2013), 612–625.
65. 65 McNab, F, Mayer-Barber, K, Sher, A, Wack, A, O'Garra, A, Type I interferons in infectious disease. Nat Rev Immunol 15 (2015), 87–103.
66. 66 Teles, RM, Graeber, TG, Krutzik, SR, Montoya, D, Schenk, M, Lee, DJ, et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science 339 (2013), 1448–1453.
67. 67 Roy, S, Gao, G, Lu, Y, Zhou, X, Lock, M, Calcedo, R, et al. Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. Hum Gene Ther 15 (2004), 519–530.
68. 68 Stylianou, E, Griffiths, KL, Poyntz, HC, Harrington-Kandt, R, Dicks, MD, Stockdale, L, et al. Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A. Vaccine 33 (2015), 6800–6808.
69. 69 Jeyanathan, M, Thanthrige-Don, N, Afkhami, S, Lai, R, Damjanovic, D, Zganiacz, A, et al. Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection. Mucosal Immunol 8 (2015), 1373–1387.
70. 70 Lambert, LC, Fauci, AS, Influenza vaccines for the future. N Engl J Med 363 (2010), 2036–2044.
71. 71 Hoelscher, MA, Garg, S, Bangari, DS, Belser, JA, Lu, X, Stephenson, I, et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367 (2006), 475–481.
72. 72 Van Kampen, KR, Shi, Z, Gao, P, Zhang, J, Foster, KW, Chen, DT, et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23 (2005), 1029–1036.
73. 73 Gurwith, M, Lock, M, Taylor, EM, Ishioka, G, Alexander, J, Mayall, T, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 13 (2013), 238–250.
74. 74 Roy, S, Kobinger, GP, Lin, J, Figueredo, J, Calcedo, R, Kobasa, D, et al. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine 25 (2007), 6845–6851.
75. 75 Antrobus, L, Berthoud, TK, Dicks, MD, Hill, AVS, Lambe, T, Gilbert, SC, et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza a antigens. Mol Ther 22 (2014), 668–674.
76. 76 Price, GE, Soboleski, MR, Lo, CY, Misplon, JA, Quirion, MR, Houser, KV, et al. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One, 5, 2010, e13162.
77. 77 Kim, EH, Park, HJ, Han, GY, Song, MK, Pereboev, A, Hong, JS, et al. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice. J Virol 88 (2014), 9693–9703.
78. 78 Krammer, F, Palese, P, Universal influenza virus vaccines: need for clinical trials. Nat Immunol 15 (2014), 3–5.
79. 79 McMichael, AJ, Borrow, P, Tomaras, GD, Goonetilleke, N, Haynes, BF, The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 10 (2010), 11–23.
80. 80 Weaver, EA, et al. Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV. PLoS One, 8, 2013, e67574.
81. 81 Nath, BM, Schumann, KE, Boyer, JD, The chimpanzee and other non-human-primate models in HIV-1 vaccine research. Trends Microbiol 8 (2000), 426–431.
82. 82 Shiver, JW, Fu, TM, Chen, L, Casimiro, DR, Davies, ME, Evans, RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 (2002), 331–335.
83. 83 Priddy, FH, Brown, D, Kublin, J, Monahan, K, Wright, DP, Lalezari, J, et al., Merck V520-016 Study Group, Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 46 (2008), 1769–1781.
84. 84 Buchbinder, SP, Mehrotra, DV, Duerr, A, Fitzgerald, DW, Mogg, R, Li, D, et al., Step Study Protocol Team, Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372 (2008), 1881–1893.
85. 85 Gray, GE, Allen, M, Moodie, Z, Churchyard, G, Bekker, LG, Nchabeleng, M, et al., HVTN 503/Phambili study team, Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 11 (2011), 507–515.
86. 86 Duerr, A, Huang, Y, Buchbinder, S, Coombs, RW, Sanchez, J, del Rio, C, et al., Step/HVTN 504 Study Team, Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis 206 (2012), 258–266.
87. 87 Qureshi, H, Genescà, M, Fritts, L, McChesney, MB, Robert-Guroff, M, Miller, CJ, Infection with host-range mutant adenovirus 5 suppresses innate immunity and induces systemic CD4+ T cell activation in rhesus macaques. PLoS One, 9, 2014, e106004.
88. 88 Hammer, SM, Sobieszczyk, ME, Janes, H, Karuna, ST, Mulligan, MJ, Grove, D, et al., HVTN 505 Study Team, Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 369 (2013), 2083–2092.
89. 89 Herath, S, Le Heron, A, Colloca, S, Bergin, P, Patterson, S, Weber, J, et al. Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag-pol-nef antigen. Vaccine 33 (2015), 7283–7289.
90. 90 Frahm, N, DeCamp, AC, Friedrich, DP, Carter, DK, Defawe, OD, Kublin, JG, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 122 (2012), 359–367.